Carnegie Mellon aims to develop a means to rapidly assess CQAs of mRNA LNPs used in mRNA-based vaccines through capillary electrophoresis (CE). The method is a form of capillary electrophoresis (CE), a widely accepted, miniaturizable, and easily deployed analytical technique, with several commercial platforms available for use in biomanufacturing facilities and clinical diagnostic labs. CE uses a rapid, surfactant-based form of electrophoretic DNA and RNA separation that characterizes size resolution appropriate for mRNA used as vaccine feedstocks.
Carnegie Mellon University will present:
The project will demonstrate a transformative means to rapidly and accurately characterize nanoparticles used in COVID-19 vaccines.
Since electrophoresis instrumentation is relatively cheap and easy to use, the method established could be deployed in biomanufacturing and routine testing of stocks at point-of-use to ensure product safety.
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.
Carnegie Mellon University